Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II study of docetaxel + prednisone with or without metronomic cyclophosphamide for hormone-refractory prostate cancer
2007-002331-89Phase 2Completed
- Sponsor
- Medical Faculty Magdeburg
- Start
- Jun 2007
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in castration-resistant prostate cancer (CRPC) comparing Docetaxel + prednisone with Docetaxel + prednisone + metronomic cyclophosphamide (2 arms). Primary endpoint: Overall response rate. Started Jun 2007; status: completed.
02
Drugs
docetaxelprednisonecyclophosphamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2007-002331-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002331-89.